All sales are final once shipped
Interestingly, the SURMOUNT-5 trial found that gastrointestinal adverse events causing treatment discontinuation occurred in 5.6% of semaglutide users compared to only 2.7% of tirzepatide users
This is consistent with how platform markets evolve: peak experimentation is followed by consolidation around a smaller number of scalable winners
second link Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ, Hovingh GK, Kitzman DW, Mller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsk V, Merkely B, Nez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN
Each compound has its own Phase 2 and Phase 3 dataset